To evaluate the long-term efficacy and safety of lixisenatide, a short-acting, prandial glucagon-like peptide-1 receptor agonists (GLP-1 RA) as add-on therapy in type 2 diabetes mellitus.
Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme / Broglio, Fabio; Mannucci, Edoardo; Napoli, Raffaele; Nicolucci, Antonio; Purrello, Francesco; Nikonova, Elena; Stager, William; Trevisan, Roberto. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - 19:2(2017), pp. 248-256-256. [10.1111/dom.12810]
Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme
Napoli, Raffaele;
2017
Abstract
To evaluate the long-term efficacy and safety of lixisenatide, a short-acting, prandial glucagon-like peptide-1 receptor agonists (GLP-1 RA) as add-on therapy in type 2 diabetes mellitus.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
